NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019) (subscription required, but it’s free)

• Subsequent Therapy for ROS1 Rearrangement-Positive Metastatic NSCLC (NSCL-24)

• Lorlatinib (category 2A) added as a treatment option, after progression on crizotinib or ceritinib.